Hutchison China Medi (HCM); Initiates ahase Ib/II PoC trial of Sulfatinib

Published on 23-07-2018 07:09:31
Author Sparks Team

HCM has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine tumors (“NET”) patients and in biliary tract cancer (“BTC”) patients in the U.S.

Sulfatinib is an oral small molecule angio-immuno kinase inhibitor that can simultaneously block tumor angiogenesis and immune evasion. This study is a multi-center, single-arm, open-label study to evaluate the efficacy and safety of sulfatinib as a monotherapy in (a) patients with advanced BTC that have progressed on standard first-line chemotherapy, and (b) in patients with advanced pancreatic NET.

Share this with friends and colleagues